Teva Pharmaceuticals, established in 1901, is a global pharmaceutical company. The company is into development, production and marketing of a wide range of specialty medicines, generic and OTC products, active pharmaceutical ingredients (API) and nov... More
WYETH TEVA PHARMA |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
WYETH Mar-14 |
TEVA PHARMA Dec-13 |
WYETH/ TEVA PHARMA |
5-Yr Chart Click to enlarge
|
||
High | Rs | 1,065 | 3,459 | - | |
Low | Rs | 553 | 3,005 | - | |
Sales per share (Unadj.) | Rs | 289.5 | 1,985.4 | - | |
Earnings per share (Unadj.) | Rs | 38.7 | 124.0 | - | |
Cash flow per share (Unadj.) | Rs | 39.9 | 284.5 | - | |
Dividends per share (Unadj.) | Rs | 145.00 | 108.57 | - | |
Avg Dividend yield | % | 17.9 | 3.4 | 533.6% | |
Book value per share (Unadj.) | Rs | 118.5 | 2,205.4 | - | |
Shares outstanding (eoy) | m | 22.72 | 848.00 | - | |
Bonus / Rights / Conversions | 0 | 0 | - | ||
Price / Sales ratio | x | 2.8 | 1.6 | 171.7% | |
Avg P/E ratio | x | 20.9 | 26.1 | 80.2% | |
P/CF ratio (eoy) | x | 20.3 | 11.4 | 178.5% | |
Price / Book Value ratio | x | 6.8 | 1.5 | 465.7% | |
Dividend payout | % | 374.7 | 87.5 | 428.0% | |
Avg Mkt Cap | Rs m | 18,381 | 2,741,007 | 0.7% | |
No. of employees | `000 | NA | 44.9 | 0.0% | |
Total wages/salary | Rs m | 359 | 0 | - | |
Avg. sales/employee | Rs Th | 0 | 37,459.7 | - | |
Avg. wages/employee | Rs Th | 0 | 0 | - | |
Avg. net profit/employee | Rs Th | 0 | 2,340.1 | - |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 6,577 | 1,683,624 | 0.4% | |
Other income | Rs m | 347 | 0 | - | |
Total revenues | Rs m | 6,925 | 1,683,624 | 0.4% | |
Gross profit | Rs m | 1,023 | 461,061 | 0.2% | |
Depreciation | Rs m | 27 | 136,089 | 0.0% | |
Interest | Rs m | 4 | 33,069 | 0.0% | |
Profit before tax | Rs m | 1,339 | 291,903 | 0.5% | |
Minority Interest | Rs m | 0 | 1,326 | 0.0% | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | -191,619 | -0.0% | |
Tax | Rs m | 460 | -3,564 | -12.9% | |
Profit after tax | Rs m | 879 | 105,175 | 0.8% | |
Gross profit margin | % | 15.6 | 27.4 | 56.8% | |
Effective tax rate | % | 34.3 | -1.2 | -2,811.9% | |
Net profit margin | % | 13.4 | 6.2 | 214.0% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 3,964 | 1,137,114 | 0.3% | |
Current liabilities | Rs m | 2,081 | 991,659 | 0.2% | |
Net working cap to sales | % | 28.6 | 8.6 | 331.4% | |
Current ratio | x | 1.9 | 1.1 | 166.1% | |
Inventory Days | Days | 35 | 91 | 38.7% | |
Debtors Days | Days | 278 | 96 | 289.4% | |
Net fixed assets | Rs m | 878 | 549,909 | 0.2% | |
Share capital | Rs m | 227 | 4,144 | 5.5% | |
Net worth | Rs m | 2,693 | 1,870,187 | 0.1% | |
Long term debt | Rs m | 25 | 860,875 | 0.0% | |
Total assets | Rs m | 4,842 | 3,847,621 | 0.1% | |
Interest coverage | x | 306.0 | 9.8 | 3,113.5% | |
Debt to equity ratio | x | 0 | 0.5 | 2.0% | |
Sales to assets ratio | x | 1.4 | 0.4 | 310.4% | |
Return on assets | % | 18.2 | 3.6 | 507.9% | |
Return on equity | % | 32.6 | 5.6 | 580.6% | |
Return on capital | % | 49.4 | 4.9 | 1,002.2% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 1,188 | 268,283 | 0.4% | |
From Investments | Rs m | 287 | -95,063 | -0.3% | |
From Financial Activity | Rs m | -4,296 | -321,823 | 1.3% | |
Net Cashflow | Rs m | -2,821 | -148,604 | 1.9% |
Compare WYETH With: ADCOCK INGRAM (S. Africa) MYLAN (US) ACTAVIS (US)
Compare WYETH With: TORRENT PHARMA GENNEX LAB. LACTOSE INDIA SAMRAT PHARMA ZIM LABORATORIES
Asian shares slipped before a Bank of Japan policy decision where authorities are likely to bring an end to the world's last negative rates regime.